glanatec and butaprost
glanatec has been researched along with butaprost* in 1 studies
Other Studies
1 other study(ies) available for glanatec and butaprost
Article | Year |
---|---|
Simultaneous Use of ROCK Inhibitors and EP2 Agonists Induces Unexpected Effects on Adipogenesis and the Physical Properties of 3T3-L1 Preadipocytes.
To elucidate the additive effects of an EP2 agonist, omidenepag (OMD) or butaprost (Buta) on the Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitor, ripasudil (Rip) on adipose tissue, two- or three-dimension (2D or 3D) cultures of 3T3-L1 cells were analyzed by lipid staining, the mRNA expression of adipogenesis-related genes, extracellular matrix (ECM) molecules including collagen (Col) -1, -4 and -6, and fibronectin (Fn), and the sizes and physical properties of 3D organoids, as measured by a micro-squeezer. The results indicate that adipogenesis induced (1) an enlargement of the 3D organoids; (2) a substantial enhancement in lipid staining as well as the expression of the Topics: 3T3-L1 Cells; Adipogenesis; Alprostadil; Animals; Drug Evaluation, Preclinical; Drug Interactions; Glycine; Isoquinolines; Mice; Organoids; Pyrazoles; Pyridines; Receptors, Prostaglandin E, EP2 Subtype; rho-Associated Kinases; Sulfonamides | 2021 |